CTSO

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q2 2021 Results - Earnings Call Transcript

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

Here's Why Cytosorbents Is Up 17% Today